Startseite>>Signaling Pathways>> Ox Stress Reagents>> Lipid Peroxidation>>2,3-dinor-8-iso Prostaglandin F2α

2,3-dinor-8-iso Prostaglandin F2α (Synonyms: 2,3-dinor-iPF2α-III, 2,3-dinor-8-iso PGF2α)

Katalog-Nr.GC40416

8-iso Prostaglandin F2α (8-iso PGF2α; 8-isoprostane) is a prostaglandin-like product of non-specific lipid peroxidation.

Products are for research use only. Not for human use. We do not sell to patients.

2,3-dinor-8-iso Prostaglandin F2α Chemische Struktur

Cas No.: 221664-05-7

Größe Preis Lagerbestand Menge
25μg
111,00 $
Auf Lager
50μg
213,00 $
Auf Lager
100μg
401,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

8-iso Prostaglandin F2α (8-iso PGF2α; 8-isoprostane) is a prostaglandin-like product of non-specific lipid peroxidation. 2,3-dinor-8-iso PGF2α is a metabolite of 8-iso PGF2α in humans and rats. In these species, exogenously infused 8-iso PGF2α is converted to 2,3-dinor-8-iso PGF1α and (2,3-dinor-8-iso PGF2α. Rat hepatocytes further metabolize 8-iso PGF2α to another β-oxidation product, 2,3,4,5-tetranor-8-iso PGF2α. 2,3-dinor-8-iso PGF2α is present in normal human urine at concentrations of 200-300 pg/ml. Its concentration is increased in conditions of oxidative injury (for example, smoking), and correlates well with that of the parent isoprostane, 8-iso PGF2α.

Bewertungen

Review for 2,3-dinor-8-iso Prostaglandin F2α

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 2,3-dinor-8-iso Prostaglandin F2α

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.